Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Allelic loss of 10q is a common genetic event in malignant gliomas, with three 10q tumor suppressor genes, ERCC6, PTEN, and DMBT1, putatively implicated in the most common type of malignant glioma,
glioblastoma
.
Anaplastic oligodendroglioma
, another type of malignant glioma, provides a unique opportunity to study the relevance of particular genetic alterations to chemosensitivity and survival. We therefore analyzed these three genes in 72 anaplastic oligodendrogliomas. Deletion mapping demonstrated 10q loss in 14 of 67 informative cases, with the PTEN and DMBT1 regions involved in all deletions but with the ERCC6 locus spared in two cases. Seven tumors had PTEN gene alterations; two had homozygous DMBT1 deletions, but at least one reflected unmasking of a germline DMBT1 deletion. No mutations were found in ERCC6 exon 2. Chemotherapeutic response occurred in two of the seven tumors with PTEN alterations, but with unexpected short survival times. PTEN gene alterations were not associated with poor therapeutic response in multivariate analysis, but were independently predictive of poor prognosis even after multivariate adjustment for both 10q and 1p loss. In anaplastic oligodendroglioma, therefore, PTEN is a target of 10q loss, and PTEN alterations are associated with poor prognosis, even in chemosensitive cases.
...
PMID:PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. 1143 83
900 to 1000 new cases of primary brain tumour occur each year in Denmark, and half of them are gliomas. The treatment is cytoreductive surgery, followed by radiation therapy and chemotherapy. Radiation therapy has a definite place in the treatment of low-grade gliomas, but the timing is a matter of dispute. Patients with
Glioblastoma
Multiform should be treated with concomitant radiation therapy and temozolamide, followed by adjuvant temozolamide. Anaplastic astrocytomas should be treated with postoperative radiation therapy with or without adjuvant chemotherapy.
Anaplastic oligodendroglioma
should be treated with radiation therapy only.
...
PMID:[Gliomas in adults: primary non-surgical treatment]. 1713 3